Replies to post #141308 on Biotech Values

[DewDiligence]

ABT declares 355th consecutive quarterly dividend:

http://finance.yahoo.com/news/abbott-declares-355th-consecutive-quarterly-150000601.html

Normally, I wouldn’t bother posting this, but there’s an impending issue: how will the dividend on the current Abbott be divided between the new Abbott and the drug spin-off, Abbvie? My supposition is that the new Abbott (#msg-75216470) will get 60-70% of it.

[DewDiligence]

ABT introduces Ensure Complete adult nutrition shake:

http://finance.yahoo.com/news/abbott-introduces-ensure-complete-shakes-120000691.html

The Nutritionals business segment will comprise about 25% of sales at the new (i.e. post-ABBV spinoff) ABT. It is ABT’s fastest-growing segment, especially in emerging markets.

[DewDiligence]

The only reason I can see to be gun-shy about the “new” ABT (post-ABBV-spinoff) is that there has recently been some very heavy insider selling…

Miles White (CEO):
http://www.sec.gov/Archives/edgar/data/1800/000117911012015702/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012015703/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012015704/xslF345X03/edgar.xml

Heather Mason, SVP (Diabetes Care):
http://www.sec.gov/Archives/edgar/data/1800/000117911012012395/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012012394/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012012393/xslF345X03/edgar.xml

Michael Warmuth, SVP (Established Products [i.e. branded generics]):
http://www.sec.gov/Archives/edgar/data/1800/000117911012013059/xslF345X03/edgar.xml

Brian Blaser, EVP (Diagnostics):
http://www.sec.gov/Archives/edgar/data/1800/000117911012015434/xslF345X03/edgar.xml

John Landgraf, EVP (Nutritional Products)
http://www.sec.gov/Archives/edgar/data/1800/000117911012013703/xslF345X03/edgar.xml

Stephen Fussell, SVR (HR):
http://www.sec.gov/Archives/edgar/data/1800/000117911012015433/xslF345X03/edgar.xml


All told, that’s a lot of selling, especially by Mr. White and Ms. Mason.


There has also been a little selling by one insider who will end up with ABBV after the split…Carlos Alban, SVP:
http://www.sec.gov/Archives/edgar/data/1800/000117911012014554/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012014369/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012014151/xslF345X03/edgar.xml

[DewDiligence]

ABT launches Tecnis, the first IOL for US cataract-surgery market that corrects for astigmatism of >=1 diopter:

http://finance.yahoo.com/news/abbott-announces-fda-approval-u-120000776.html

[DewDiligence]

ABT posted solid 1Q13 results in its first quarter as a standalone (i.e. ex-AbbVie) company:

http://finance.yahoo.com/news/abbott-reports-first-quarter-2013-114400616.html

Sales in emerging markets grew 15% YoY and comprised 40% of total corporate sales in the quarter; this proportion is expected to increase to 50% within the next few years.

Since the separation of ABT and ABBV on 12/31/12, ABT’s share price has risen 19%.